Technical Data
045396
YC-1 (3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole)
1mg
Biochemicals Storage: 4C/-20CShipping: Blue Ice
Nitric oxide (NO) independent, superoxide-sensitive soluble guanylyl cyclase (sGC) activator. Induces concentration-dependent increase in cGMP levels. Inhibits platelet adhesion to collagen. Thombosis inhibitor. Non-specific phosphodiesterase inhibitor. Na+ channel blocker. Anticancer compound. HIF-alpha inhibitor. Blocks angiogenesis. Tumor growth inhibitor. Apoptosis inducer. NK cell differentiation enhancer.

Storage and Stability:
Short-term Storage: +4C
Long-term Storage: -20C
Stable for at least 2 years after receipt when stored at +4C.

CAS Number:
170632-47-0

Molecular Formula:
C19H16N2O2

Molecular Weight:
304.40
Purity: >98% (NMR)

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference:
YC-1, a novel activator of platelet guanylate cyclase: F.N. Ko, et al.; Blood 84, 4226 (1994)
YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase: C.C. Wu, et al.; Br. J. Pharmacol. 116, 1973 (1995)
YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice: C.M. Teng, et al.; Eur. J. Pharmacol. 320, 161 (1997)
Mechanism of YC-1-induced activation of soluble guanylyl cyclase: A. Friebe & D. Koesling; Mol. Pharmacol. 53, 123 (1998)
BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase: M. Koglin, et al.; BBRC 292, 1057 (2002)
Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition: G. Garthwaite, et al.; Mol. Pharmacol. 61, 97 (2002)
YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1: E.J. Yeo, et al.; J. Natl. Cancer Inst. 95, 516 (2003)
Versatile pharmacological actions of YC-1: anti-platelet to anticancer: Y.S. Chun, et al.; Cancer Lett. 207, 1 (2004) (Review)
A Novel Drug Binding Site on Voltage-Gated Sodium Channels in Rat Brain: D. R. Riddall, et al.; Mol. Pharmacol. 69, 278 (2006)
Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading: D.H. Shin, et al.; Cancer Lett. 255, 107 (2007)
YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway: S.Y. Wu, et al.; Br. J. Pharmacol. 155, 505 (2008)
YC-1 enhances natural killer cell differentiation from hematopoietic stem cells: S. Yun, et al.; Int. Immunopharmacol. 10, 481 (2010)


Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.